GTHA has learned that a group out of the United Kingdom has been circulating a document claiming to be buying GeneThera and that GeneThera is declaring bankruptcy. The Company has never heard of the group and has no intention of filing for bankruptcy protection.
Commenting on the document, Dr. Tony Milici, CEO of GeneThera said, "This is an obvious attempt to depress the price of the stock of GeneThera for personal gain. There are many organizations in the world that seek to profit by these means. GeneThera will aggressively combat these deceitful behaviors." Milici continued, "The Company has never been stronger in its drive for successful commercialization of its live animal tests. I urge our shareholders to read our recent releases at www.genethera.net about lab facilities being opened in both Northern Italy and Mexico and to generate their own opinions about what that means to the success of the Company."
ABOUT GENETHERA, INC.:
GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease - a disease affecting elk and deer in North America, E.Coli 0157:H7 and Johne's Disease, diseases affecting cattle worldwide.
``Safe Harbor'' Statement: Certain statements in this release are ``forward-looking'' statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.
Contact: GeneThera, Inc. Dr. Tony Milici, 303-463-6371 http://www.genethera.net
Source: GeneThera, Inc.
